AlzeCure Pharma AB (publ) (STO:ALZCUR)
Sweden · Delayed Price · Currency is SEK 8.08
+0.14 (1.76%)
Sep 2, 2026, 5:29 PM CET
AlzeCure Pharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 13.49 | 50.34 | 31.5 | 29.1 | 25.58 | 41.74 |
Cash & Short-Term Investments | 13.49 | 50.34 | 31.5 | 29.1 | 25.58 | 41.74 |
Cash Growth | 7.28% | 59.81% | 8.24% | 13.77% | -38.73% | -62.88% |
Accounts Receivable | 0.11 | - | 0.04 | - | - | - |
Other Receivables | 6.61 | 3.34 | 1.77 | 1.47 | 1.38 | 1.54 |
Receivables | 6.72 | 3.34 | 1.8 | 1.47 | 1.38 | 1.54 |
Prepaid Expenses | 98.65 | 1.2 | 0.61 | 1.04 | 0.55 | 0.92 |
Other Current Assets | - | 0.09 | - | - | - | - |
Total Current Assets | 118.87 | 54.96 | 33.9 | 31.61 | 27.51 | 44.2 |
Property, Plant & Equipment | 3.49 | 4.06 | 5.33 | 0.38 | 0.85 | 1.42 |
Other Intangible Assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
Other Long-Term Assets | - | -0 | - | - | 42.46 | 0.01 |
Total Assets | 122.37 | 59.04 | 39.25 | 32 | 70.84 | 45.65 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.57 | 4.16 | 2.69 | 2.69 | 4.85 | 5.97 |
Accrued Expenses | 17.12 | 6.67 | 5.25 | 4.95 | 5.18 | 6.38 |
Current Portion of Leases | - | 1.3 | 1.3 | - | - | - |
Current Unearned Revenue | - | 11.06 | - | - | - | - |
Other Current Liabilities | 7.27 | 0.38 | 0.31 | 0.59 | 0.33 | 0.32 |
Total Current Liabilities | 28.95 | 23.56 | 9.55 | 8.23 | 10.35 | 12.67 |
Long-Term Leases | 2.01 | 2.56 | 3.64 | - | - | - |
Total Liabilities | 30.96 | 26.12 | 13.18 | 8.23 | 10.35 | 12.67 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 2.87 | 2.87 | 2.21 | 1.55 | 1.27 | 0.94 |
Additional Paid-In Capital | 453.27 | 453.27 | 399.43 | 362.44 | 361.98 | 278.84 |
Retained Earnings | -364.73 | -423.22 | -375.57 | -340.22 | -303.05 | -246.81 |
Comprehensive Income & Other | - | - | - | - | 0.28 | - |
Shareholders' Equity | 91.41 | 32.92 | 26.07 | 23.77 | 60.48 | 32.97 |
Total Liabilities & Equity | 122.37 | 59.04 | 39.25 | 32 | 70.84 | 45.65 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.01 | 3.86 | 4.93 | - | - | - |
Net Cash (Debt) | 11.48 | 46.48 | 26.57 | 29.1 | 25.58 | 41.74 |
Net Cash Growth | -8.69% | 74.96% | -8.71% | 13.77% | -38.73% | -62.88% |
Net Cash Per Share | 0.10 | 0.46 | 0.34 | 0.47 | 0.54 | 1.11 |
Filing Date Shares Outstanding | 137.9 | 114.91 | 88.3 | 62.09 | 62.09 | 37.77 |
Total Common Shares Outstanding | 137.9 | 114.91 | 88.3 | 62.09 | 62.09 | 37.77 |
Working Capital | 89.91 | 31.4 | 24.36 | 23.38 | 17.15 | 31.53 |
Book Value Per Share | 0.66 | 0.29 | 0.30 | 0.38 | 0.97 | 0.87 |
Tangible Book Value | 91.39 | 32.9 | 26.05 | 23.76 | 60.47 | 32.96 |
Tangible Book Value Per Share | 0.66 | 0.29 | 0.30 | 0.38 | 0.97 | 0.87 |
Machinery | - | 3.02 | 3.02 | 2.9 | 2.9 | 2.9 |